JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcial, M.
Right arrow Articles by Kuritzkes, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcial, M.
Right arrow Articles by Kuritzkes, D. R.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, September 2006, p. 3384-3387, Vol. 44, No. 9
0095-1137/06/$08.00+0     doi:10.1128/JCM.00666-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Performance of Human Immunodeficiency Virus Type 1 gp41 Assays for Detecting Enfuvirtide (T-20) Resistance Mutations

Michelle Marcial,1 Jing Lu,1 Steven G. Deeks,2 Rainer Ziermann,3,{dagger} and Daniel R. Kuritzkes1*

Section of Retroviral Therapeutics, Brigham and Women's Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts,1 Department of Medicine, University of California, San Francisco, and San Francisco General Hospital, San Francisco, California,2 Diagnostics Division, Bayer HealthCare LLC, Berkeley, California3

Received 28 March 2006/ Returned for modification 16 May 2006/ Accepted 5 July 2006

The performance of a gp41 assay, created using reagents designed for use with the OpenGene DNA Sequencing System, was evaluated using a panel of plasma samples obtained from enfuvirtide-naive and -experienced human immunodeficiency virus type 1-infected subjects. Resulting sequence data were highly accurate compared to a "home brew" assay and clonal sequence analysis.

* Corresponding author. Mailing address: Brigham and Women's Hospital, 65 Landsdowne Street, Room 449, Cambridge, MA 02139. Phone: (617) 768-8371. Fax: (617) 768-8738. E-mail: dkuritzkes{at}partners.org.

{dagger} Present address: Novartis Vaccines and Diagnostics, Chiron, Inc., Emeryville, Calif.

Journal of Clinical Microbiology, September 2006, p. 3384-3387, Vol. 44, No. 9
0095-1137/06/$08.00+0     doi:10.1128/JCM.00666-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.